XML 45 R26.htm IDEA: XBRL DOCUMENT v3.25.0.1
Award Timing Disclosure
12 Months Ended
Dec. 31, 2024
Feb. 01, 2024
USD ($)
security
$ / shares
Award Timing Disclosures [Line Items]    
Award Timing MNPI Disclosure

Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information

From time to time, we grant equity awards, including stock options, to our employees, including our NEOs.  Our typical practice is to grant employee stock options on the first business day of the month following the month in which the options are approved (or on the same day of approval if such approval is on the first business day of a month). We typically grant annual refresh employee option grants in the first quarter of each fiscal year, which refresh grants are typically approved at a regularly scheduled meeting of the Compensation Committee occurring in such quarter.  In addition, non-employee directors receive automatic grants of initial and annual stock option awards, at the time of a director’s initial appointment or election to the board and at the time of each annual meeting of our stockholders, respectively, pursuant to our non-employee director compensation policy, as further described under the heading, “Non-Employee Director Compensation”. We do not otherwise maintain any written policies on the timing of awards of stock options, stock appreciation rights, or similar instruments with option-like features. The Compensation Committee considers whether there is any material nonpublic information (“MNPI”) about our company when determining the timing of stock option grants and it does not seek to time the award of stock options in relation to the Company’s public disclosure of MNPI. We have not timed the release of MNPI for the purpose of affecting the value of executive compensation.

The following table is being provided pursuant to Item 402(x)(2) of Regulation S-K.

Name
(a)

    

Grant date
(b)

    

Number of
securities
underlying the
award
(c)

    

Exercise price of the
award ($/Sh)
(d)

    

Grant date fair
value of the
award
(e)

    

Percentage change in the
closing market price of the
securities underlying the
award between the trading
day ending immediately prior
to the disclosure of material
nonpublic information and the
trading day beginning
immediately following the
disclosure of material
nonpublic information
(f)(1)

 

Neal Walker

February 1, 2024

497,000

$

1.20

$

421,586

(5.8)

%

Kevin Balthaser

February 1, 2024

206,500

$

1.20

$

179,003

(5.8)

%

(1)The option grants reported in this table were made two business days before the Company filed (i) a Form 8-K under Item 5.02 reporting the departure of our Chief Medical Officer, the entry into an amended and restated employment agreement with our Chief Scientific Officer, and the entry into a separation agreement with our former Chief Executive Officer and President following his previously reported departure and (ii) a Form 8-K amendment under Item 5.02 reporting the entry into a compensatory letter agreement with Dr. Walker following his previously reported appointment as our Interim Chief Executive Officer.
 
Award Timing Method

From time to time, we grant equity awards, including stock options, to our employees, including our NEOs.  Our typical practice is to grant employee stock options on the first business day of the month following the month in which the options are approved (or on the same day of approval if such approval is on the first business day of a month). We typically grant annual refresh employee option grants in the first quarter of each fiscal year, which refresh grants are typically approved at a regularly scheduled meeting of the Compensation Committee occurring in such quarter.  In addition, non-employee directors receive automatic grants of initial and annual stock option awards, at the time of a director’s initial appointment or election to the board and at the time of each annual meeting of our stockholders, respectively, pursuant to our non-employee director compensation policy, as further described under the heading, “Non-Employee Director Compensation”. We do not otherwise maintain any written policies on the timing of awards of stock options, stock appreciation rights, or similar instruments with option-like features. The Compensation Committee considers whether there is any material nonpublic information (“MNPI”) about our company when determining the timing of stock option grants and it does not seek to time the award of stock options in relation to the Company’s public disclosure of MNPI. We have not timed the release of MNPI for the purpose of affecting the value of executive compensation.

 
Awards Close in Time to MNPI Disclosures, Table

Name
(a)

    

Grant date
(b)

    

Number of
securities
underlying the
award
(c)

    

Exercise price of the
award ($/Sh)
(d)

    

Grant date fair
value of the
award
(e)

    

Percentage change in the
closing market price of the
securities underlying the
award between the trading
day ending immediately prior
to the disclosure of material
nonpublic information and the
trading day beginning
immediately following the
disclosure of material
nonpublic information
(f)(1)

 

Neal Walker

February 1, 2024

497,000

$

1.20

$

421,586

(5.8)

%

Kevin Balthaser

February 1, 2024

206,500

$

1.20

$

179,003

(5.8)

%

(1)The option grants reported in this table were made two business days before the Company filed (i) a Form 8-K under Item 5.02 reporting the departure of our Chief Medical Officer, the entry into an amended and restated employment agreement with our Chief Scientific Officer, and the entry into a separation agreement with our former Chief Executive Officer and President following his previously reported departure and (ii) a Form 8-K amendment under Item 5.02 reporting the entry into a compensatory letter agreement with Dr. Walker following his previously reported appointment as our Interim Chief Executive Officer.
 
Neal Walker    
Awards Close in Time to MNPI Disclosures    
Name   Neal Walker
Underlying Securities | security   497,000
Exercise Price | $ / shares   $ 1.2
Fair Value as of Grant Date | $   $ 421,586
Underlying Security Market Price Change   (5.8)
Kevin Balthaser    
Awards Close in Time to MNPI Disclosures    
Name   Kevin Balthaser
Underlying Securities | security   206,500
Exercise Price | $ / shares   $ 1.2
Fair Value as of Grant Date | $   $ 179,003
Underlying Security Market Price Change   (5.8)